AIM: To determine the risk of chronic obstructive pulmonary disease (COPD) associated with polymorphisms in the glutathione S-transferase (GST) M1, GST T1, and microsomal epoxide hydrolase (EPHX1) genes in a cohort of Slovak population. METHODS: Two hundred and seventeen patients with the diagnosis of COPD and 160 control subjects were enrolled in the study. Blood samples were collected from all subjects and the DNA from peripheral blood lymphocytes was used for subsequent genotyping assays, using polymerase chain reaction and restriction fragment-length polymorphism methods. RESULTS: In an unadjusted model, an increased risk for COPD was observed in subjects with EPHX1 His113-His113 genotype (odds ratio [OR], 2.32; 95% confidence interval [CI], 1.20-4.69; P=0.008), compared with the carriers of the Tyr113 allele. However, after the adjustments for age, sex, and smoking status, the risk was not significant (adjusted OR, 1.79; 95% CI, 0.91-3.53; P=0.093). In a combined analysis of gene polymorphisms, the genotype combination EPHX1 His113-His113/GSTM1 null significantly increased the risk of COPD in both, unadjusted (OR, 5.08; 95% CI, 1.70-20.43; P=0.001) and adjusted model (OR, 4.87; 95% CI, 1.57-15.13; P=0.006). CONCLUSION: Although none of the tested gene polymorphisms was significantly related to an increased risk of COPD alone, our results suggest that the homozygous exon 3 mutant variant of EPHX1 gene in the combination with GSTM1 null genotype is a significant predictor of increased susceptibility to COPD in the Slovak population. The findings of the present study emphasize the importance of detoxifying and antioxidant pathways in the pathogenesis of COPD.
AIM: To determine the risk of chronic obstructive pulmonary disease (COPD) associated with polymorphisms in the glutathione S-transferase (GST) M1, GST T1, and microsomal epoxide hydrolase (EPHX1) genes in a cohort of Slovak population. METHODS: Two hundred and seventeen patients with the diagnosis of COPD and 160 control subjects were enrolled in the study. Blood samples were collected from all subjects and the DNA from peripheral blood lymphocytes was used for subsequent genotyping assays, using polymerase chain reaction and restriction fragment-length polymorphism methods. RESULTS: In an unadjusted model, an increased risk for COPD was observed in subjects with EPHX1 His113-His113 genotype (odds ratio [OR], 2.32; 95% confidence interval [CI], 1.20-4.69; P=0.008), compared with the carriers of the Tyr113 allele. However, after the adjustments for age, sex, and smoking status, the risk was not significant (adjusted OR, 1.79; 95% CI, 0.91-3.53; P=0.093). In a combined analysis of gene polymorphisms, the genotype combination EPHX1 His113-His113/GSTM1 null significantly increased the risk of COPD in both, unadjusted (OR, 5.08; 95% CI, 1.70-20.43; P=0.001) and adjusted model (OR, 4.87; 95% CI, 1.57-15.13; P=0.006). CONCLUSION: Although none of the tested gene polymorphisms was significantly related to an increased risk of COPD alone, our results suggest that the homozygous exon 3 mutant variant of EPHX1 gene in the combination with GSTM1 null genotype is a significant predictor of increased susceptibility to COPD in the Slovak population. The findings of the present study emphasize the importance of detoxifying and antioxidant pathways in the pathogenesis of COPD.
Authors: A J Sandford; T Chagani; T D Weir; J E Connett; N R Anthonisen; P D Paré Journal: Am J Respir Crit Care Med Date: 2001-02 Impact factor: 21.405
Authors: Jemma B Wilk; Anita L DeStefano; Donna K Arnett; Stephen S Rich; Luc Djousse; Robert O Crapo; Mark F Leppert; Michael A Province; L Adrienne Cupples; Daniel J Gottlieb; Richard H Myers Journal: Am J Respir Crit Care Med Date: 2003-03-13 Impact factor: 21.405
Authors: Ladina Joos; Jian-Qing He; Megan B Shepherdson; John E Connett; Nicholas R Anthonisen; Peter D Paré; Andrew J Sandford Journal: Hum Mol Genet Date: 2002-03-01 Impact factor: 6.150
Authors: Francisco Rodriguez; Rosendo Jardi; Xose Costa; Daniel Juan; Roman Galimany; Rafael Vidal; Marc Miravitlles Journal: Anal Biochem Date: 2002-09-01 Impact factor: 3.365
Authors: Jian-Qing He; Jian Ruan; John E Connett; Nicholas R Anthonisen; Peter D Paré; Andrew J Sandford Journal: Am J Respir Crit Care Med Date: 2002-08-01 Impact factor: 21.405
Authors: Ruzena Tkácová; Ján Salagovic; Marianna Ceripková; Ivan Tkác; Ján Stubna; Ivan Kalina Journal: Wien Klin Wochenschr Date: 2004-02-28 Impact factor: 1.704
Authors: Mariza de Andrade; Yan Li; Randolph S Marks; Claude Deschamps; Paul D Scanlon; Curtis L Olswold; Ruoxiang Jiang; Stephen J Swensen; Zhifu Sun; Julie M Cunningham; Jason A Wampfler; Andrew H Limper; David E Midthun; Ping Yang Journal: Cancer Prev Res (Phila) Date: 2011-11-01
Authors: Andrew J Sandford; Deepti Malhotra; H Marike Boezen; Mateusz Siedlinski; Dirkje S Postma; Vivien Wong; Loubna Akhabir; Jian-Qing He; John E Connett; Nicholas R Anthonisen; Peter D Paré; Shyam Biswal Journal: Physiol Genomics Date: 2012-06-12 Impact factor: 3.107